Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Avadel Pharmaceuticals plc (AVDL) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 154 employees
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Total Value
$761,674.61
Total Shares
85,579
Average Trade Value
$76,167.46
Most Active Insider
Ende Eric J
Total Activity: $235,218
Largest Single Transaction
$235,218
by Ende Eric J on Jan 13, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Jan 21, 2025 | 5,000 | $39,640 | 67,900 (+7.4%) | Purchase | |
|
Director
|
Jan 13, 2025 | 30,000 | $235,218 | 208,900 (+14.4%) | Purchase | |
|
Director
|
Jan 13, 2025 | 10,000 | $80,450 | 104,055 (+9.6%) | Purchase | |
|
Chief Financial Officer
Officer
|
Dec 13, 2024 | 2,300 | $24,019 | 87,800 (+2.6%) | Purchase | |
|
Chief Financial Officer
Officer
|
Dec 11, 2024 | 5,000 | $52,433 | 85,500 (+5.8%) | Purchase | |
|
Director
|
Dec 10, 2024 | 10,204 | $99,999 | 75,904 (+13.4%) | Purchase | |
|
Director
|
Dec 10, 2024 | 10,075 | $99,642 | 69,075 (+14.6%) | Purchase | |
|
Chief Executive Officer
Director, Officer
|
Dec 9, 2024 | 402 | $3,948 | 10,000 (+4.0%) | Purchase | |
|
Director
|
Dec 6, 2024 | 3,000 | $30,568 | 66,400 (+4.5%) | Purchase | |
|
Chief Executive Officer
Director, Officer
|
Dec 6, 2024 | 9,598 | $95,759 | 9,598 (+100.0%) | Purchase |